The biopharmaceutical market within the Japan and Asia-Pacific (JAPAC) region has grown consistently since 2010, specifically for emerging biopharmas (EBPs). In fact, in 2018, 80% of all biopharma pipeline projects in JAPAC were EBPs, accounting for 75% of the total clinical trial volume in the region. This growth benefits contract research organizations, pharma organizations and patients alike, but several factors must be considered for drug development safety and regulatory operations in JAPAC
Read More
Biopharma | News, Analysis, Insights - HIT Consultant
Israel Innovation Authority to Invest $31M to Establish R&D Infrastructure Center for Bio-Chips-Based Bio-Devices
What You Should Know: The Israel Innovation Authority announced today a NIS 113M ($31M USD) investment for the establishment of a center that will provide research and development (R&D) infrastructure for bio-devices based on bio-chips. The investment is part of the National Bio-Convergence Program.Bio-convergence represents the integration of biology and life sciences with engineering and software technologies. The investment is directed at companies dedicated to developing key
Read More
Walgreens and Freenome Partner to Increase Diversity in Research
What You Should Know: Walgreens and Freenome form a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for the early detection of cancer. Walgreens will combine its national footprint, patient insights, compliant recruitment technology and local infrastructure to engage diverse patient populations in Freenome’s multi-cancer research program. Walgreens will initially recruit patients across diverse populations for Freenome’s Sanderson Study, which aims to
Read More
Navigating the Challenges of Biosample Consent in Clinical Trials
In the age of biotechnology, biosample collection has become an essential part of medical research. Through this process, samples are taken from patients through a variety of sources, including blood, tissue, saliva, hair, and other bodily fluids. The samples are then analyzed for their genetic, biochemical, or physiological properties, and the findings are used to further the understanding of human health, disease and the environment. Many times, during clinical trials, sponsors will want to
Read More
3 Ways Government Can Catalyze Biomedical Innovation
What You Should Know: Deloitte has published some new research about how government can advance biomedical innovation and improve public health.The report shares insights from various government leaders and biomedical industry experts on lessons learned from the COVID-19 pandemic, what’s driving innovation, the challenges and opportunities in partnerships, and the government’s role in sustaining the biomedical industry. Understanding How the Government Can Catalyze Biomedical
Read More
Genemod Raises $4.5M to Expand Central Research Platform for Biopharma Companies
What You Should Know: Genemod, a cloud-based workspace collaboration software for biopharma R&D teams, today announced it raised $4.5 million in seed funding, co-led by defy.vc and LDV Partners, with participation from Dolby Family Ventures and Vulcan/Cercano Ventures.Genemod digitizes data capture and workflows, so scientists can collaborate easily across an organization to accelerate life sciences R&D. Digitize Research Workflows in Minutes Legacy R&D software
Read More
What to Know About Gene Therapy
Gene therapy is making a world where cancer and AIDS can be cured, and a person can alter their genetic makeup, changing the direction of their own and their offspring's evolution in the process. However, the effects of gene therapy are long-lasting, and may impact both your and the health of your future children. What Is Gene Therapy? Utilizing a gene or genes to treat or cure a disease or medical condition is known as gene therapy. Gene therapy frequently involves replacing a
Read More
How Can Biopharma Companies Sustain Growth & Innovation?
What You Should Know: - The traditional approach to fostering biopharma growth is no longer sustainable, according to Accenture research and analysis. The new research reveals perspectives on the life sciences industry based on an extensive analysis of over 300 M&A deals made by the top 30 biopharma companies between 2010–2021. - The analysis reveals multiple factors are eroding the sustainability of an inorganic growth strategy, such as rising costs of M&A,
Read More
Merck Digital Sciences Studio Launches to Support Biomedical Startups
What You Should Know: - Merck, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. - MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck. MDSS Accelerator Program Focus The MDSS is a collaboration between
Read More
Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines
What You Should Know: - Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding to expand the benefit and reach of genetic medicines. - Despite life-changing responses, existing gene therapies are highly complex, costly, and limited by complicated treatment paradigms, tractable therapeutic applications, and dose-limiting toxicities. By enabling precisely targeted, highly efficient, manufacturable “off-the-shelf” in
Read More